enGene Therapeutics Inc.
enGene Therapeutics Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||
Assets Current | ||||||||||||||||
Class B Redeemable Convertible Preferred Shares | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Class C Redeemable Convertible Preferred Shares | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Cash And Cash Equivalents At Carrying Value | 30 | 37 | 50 | 33 | 58 | 62 | 173 | 258 | 265 | 86 | 82 | |||||
Marketable Securities Current | 229 | 239 | 144 | 169 | 160 | 151 | 65 | - | - | - | - | |||||
Restricted Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Prepaid Expense And Other Assets Current | 11 | 12 | 7 | 9 | 10 | 8 | 9 | 5 | 4 | 3 | 2 | |||||
Assets Current | 270 | 289 | 201 | 211 | 228 | 222 | 247 | 263 | 270 | 90 | 85 | |||||
Marketable Securities Noncurrent | 27 | 37 | 9 | 23 | 34 | 59 | 60 | - | - | - | - | |||||
Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Operating Lease Right Of Use Asset | 7 | 7 | 8 | 8 | 2 | 2 | 2 | 2 | 2 | 2 | - | |||||
Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | |||||
Assets | 308 | 337 | 221 | 246 | 267 | 286 | 311 | 267 | 274 | 93 | 87 | |||||
Liabilities And Stockhold… | ||||||||||||||||
Liabilities Current | ||||||||||||||||
Accounts Payable Current | 2 | 2 | 7 | 2 | 2 | 3 | 1 | 3 | 0 | 1 | 1 | |||||
Accrued Liabilities And Other Liabilities | 17 | 20 | 15 | 11 | 12 | 8 | 12 | 9 | 6 | 5 | 4 | |||||
Operating Lease Liability Current | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Notes Payable Current | 0 | 0 | 8 | 5 | 4 | 2 | 1 | 1 | - | - | 1 | |||||
Liabilities Current | 21 | 25 | 32 | 20 | 18 | 13 | 15 | 13 | 6 | 7 | 5 | |||||
Long Term Notes Payable | 25 | 25 | 15 | 18 | 20 | 22 | 22 | 22 | 23 | 23 | 9 | |||||
Operating Lease Liability Noncurrent | 6 | 6 | 6 | 7 | 1 | 1 | 1 | 1 | 2 | 2 | - | |||||
Liabilities | 52 | 56 | 54 | 45 | 39 | 36 | 39 | 37 | 31 | 31 | 14 | |||||
Stockholders Equity | ||||||||||||||||
Common Stock Value | 632 | 632 | 513 | 510 | 510 | 510 | 510 | 453 | 453 | 259 | 259 | |||||
Additional Paid In Capital Common Stock | 56 | 52 | 27 | 26 | 23 | 21 | 19 | 17 | 16 | 14 | 14 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |||||
Retained Earnings Accumulated Deficit | -432 | -402 | -372 | -334 | -305 | -279 | -255 | -239 | -225 | -210 | -200 | |||||
Stockholders Equity | 255 | 282 | 168 | 201 | 227 | 250 | 273 | 230 | 243 | 62 | 72 | |||||
Preferred Stock No Par Value | - | - | - | - | - | - | - | 0 | 0 | 0 | - | |||||
Preferred Stock Shares Issued | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Liabilities And Stockholders Equity | 308 | 337 | 221 | 246 | 267 | 286 | 311 | 267 | 274 | 93 | 87 | |||||
Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Common Stock Shares Issued | 67 | 67 | 52 | 51 | 51 | 51 | 51 | 44 | 44 | 23 | 23 | |||||
Shares Outstanding | 67 | 67 | 52 | 51 | 51 | 51 | 51 | 44 | 44 | 23 | 23 | |||||
Class A Redeemable Convertible Preferred Shares | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.11% | 2.84% | -73.76% | 7.34% | - | - | - | - | - | - | - | - |
| 2025 | -14.12% | -27.10% | -26.72% | 16.92% | 17.85% | 42.15% | 27.89% | 18.98% | 33.17% | 6.16% | 11.52% | -18.36% |
| 2024 | -0.36% | -6.17% | -46.82% | 1.67% | -6.89% | -22.44% | 2.00% | 36.77% | 33.08% | 27.68% | 5.70% | -11.91% |
| 2023 | - | - | - | - | - | - | - | - | - | 86.40% | 122.69% | 83.91% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
enGene Therapeutics Inc. (ENGN) — SEC Financial Statements & Analysis
enGene Therapeutics Inc. (ENGN) is a biological products, (no diagnostic substances) company, incorporated in Z4. enGene Therapeutics Inc. trades on Nasdaq as: ENGN, ENGNW. Based on its latest SEC filing (Form 10-Q, period ending 2026-04-30), enGene Therapeutics Inc. reported a Debt-to-Equity ratio of 0.21x, a Price-to-Book (P/B) ratio of 1.99x (TTM), at a market cap of $506.90M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.21x
- P/B TTM
- 1.99x
- Market Cap
- $506.90M
Data as of 2026-04-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is enGene Therapeutics Inc. in?
enGene Therapeutics Inc. (ENGN) operates in the Biological Products, (No Diagnostic Substances) industry.
What is ENGN's market cap?
enGene Therapeutics Inc. (ENGN) has a market capitalization of $506.90M as of 2026-04-30.
What is ENGN's P/E ratio?
enGene Therapeutics Inc. (ENGN)'s trailing twelve month P/E ratio is 4.00x as of 2026-04-30.
What exchange does ENGN trade on?
enGene Therapeutics Inc. (ENGN) trades on the Nasdaq.
Where is enGene Therapeutics Inc. incorporated?
enGene Therapeutics Inc. is incorporated in Canada (Federal Level).